Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032901 · ClinicalTrials.gov registry record · Phase 3
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
A Phase 3 study of Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 20
- Study locations
NCT02032901: Completed Phase 3 study of Hepatitis C, sponsored by Bristol-Myers Squibb.
NCT02032901 is a Phase 3 study of Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 173 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02032901, a Phase 3 study of Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 20
- Study locations
Study Summary
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
Primary Outcome
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation ie., 25 IU/mL, TD or TND at follow-up Week 12. HCV RNA levels were measured by the Roche Cobas® TaqMan® HCV Test version 2.0 from the central laboratory.
Conditions Studied
Interventions
- DRUG Sofosbuvir
- DRUG Daclatasvir
Study Locations (20)
California
- Scripps Clinic - La Jolla
- Peter J Ruane MD Inc - Los Angeles
- National Research Institute - Los Angeles
- Anthony M. Mills MD Inc - Los Angeles
- Huntington Medical Research Institutes - Pasadena
- Precision Research Institute, LLC - San Diego
- Medical Associates Research Group - San Diego
- Quest Clinical Research - San Francisco
Florida
- Midland Florida Clinical Research Center, LLC - DeLand
- University of Florida Hepatology Research - Gainesville
Georgia
- Atlanta Gastroenterology Associates - Atlanta
- Gastrointestinal Specialists Of Georgia - Marietta
Maryland
- Mercy Medical Center, Inc. - Baltimore
- Digestive Disease Associates, P.A. - Baltimore
New York
- North Shore University Hospital - Manhasset
- Premier Medical Group Of The Hudson Valley, Pc - Poughkeepsie
Illinois
- Dupage Medical Group - Downers Grove
Missouri
- Kansas City Research Institute - Kansas City
New Mexico
- Southwest Care Center - Santa Fe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT02032901 record still lists
NCT02032901 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Sofosbuvir is the first listed.
NCT02032901 names 20 study sites across 9 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02032901 about?
NCT02032901 is a clinical study titled "Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV". To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
What is the current status of trial NCT02032901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2014-01. Estimated completion is 2014-12.
What conditions does trial NCT02032901 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT02032901?
The interventions under investigation include: Sofosbuvir (DRUG), Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT02032901?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02032901 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02032901's enrollment target sits among peer trials
173 44th of 106 higher than 63 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
COMPLETED · Phase 3
-
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
-
Hepatitis C Antiviral Resistance in African-Americans
COMPLETED · Phase 3
-
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 3
-
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia